BeOne Medicines Ltd
286 hedge funds and large institutions have $10.3B invested in BeOne Medicines Ltd in 2025 Q4 according to their latest regulatory filings, with 61 funds opening new positions, 112 increasing their positions, 71 reducing their positions, and 37 closing their positions.
65% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 37
58% more repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 71
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
8% more funds holding
Funds holding: 266 → 286 (+20)
1.55% less ownership
Funds ownership: 30.1% → 28.55% (-1.6%)
9% less capital invested
Capital invested by funds: $11.2B → $10.3B (-$966M)
23% less call options, than puts
Call options by funds: $34.3M | Put options by funds: $44.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$163M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$68M |
| 3 |
BlackRock
New York
|
+$59M |
| 4 |
Goldman Sachs
New York
|
+$34.2M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$31.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$84.4M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$52.4M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$36.8M |
| 4 |
Primecap Management
Pasadena,
California
|
-$32.7M |
| 5 |
Temasek Holdings
Singapore
|
-$30.1M |
ONC Hedge Fund Activity: Q4 2025 in Review
286 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q4 2025, worth a combined $10.3B — down 8.6% from $11.2B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new ONC positions and 37 closed out — a net gain of 24 holders — while 112 added to existing stakes and 71 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $163M. The largest seller was T. Rowe Price Associates, cutting an estimated $84.4M.
- 286 institutional investors held BeOne Medicines Ltd (ONC) as of Q4 2025, up from 266 in Q3 2025.
- Funds reported $10.3B of BeOne Medicines Ltd stock for Q4 2025, down 8.6% quarter-over-quarter.
- 61 funds opened new BeOne Medicines Ltd positions in Q4 2025 and 37 closed out, a net change of +24 holders.
- The largest BeOne Medicines Ltd buyer in Q4 2025 was Citadel Advisors, an estimated $163M added.
- The largest BeOne Medicines Ltd seller in Q4 2025 was T. Rowe Price Associates, an estimated $84.4M sold.
Based on aggregated 13F filings for Q4 2025.